



Company Announcement

Agenix Licensee Launches D-dimer Test in USA

17 February 2005

Attached is an announcement by Biosite Incorporated (NASDAQ: BSTE), which entered into a licensing agreement with Agenix subsidiary, AGEN Biomedical in November 2003. AGEN Biomedical will receive revenues based on antibody sales to Biosite and royalties on their product sales.

Biosite has announced that it has commenced shipments of a new rapid medical diagnostic test which incorporates AGEN's 3B6 D-dimer antibody.

The primary driver for the selection of the AGEN 3B6 D-dimer antibody by Biosite was the recognition that it is the most specific antibody for the detection of d-dimer.

<end>

For more information, please contact:

Mr Donald Home
Managing Director
Agenix Limited
Ph: 61 7 3370 6314

Agenix Limited [ASX:AGX, NASDAQ OTC: AGXLY] is a global health and biotechnology company based in Brisbane, Australia. The Company runs a suite of highly profitable and established businesses in human and animal health diagnostics, and is focused on growing its world-leading molecular diagnostic imaging R&D program. Agenix's lead candidate is its high-technology ThromboView® blood clot-imaging project, which is currently undergoing human trials. ThromboView® uses radiolabelled antibodies to locate blood clots in the body, and could revolutionise the US \$3 billion global clot diagnostic imaging market. ThromboView® is being developed with the assistance of the Federal Government through its START scheme. Agenix employs 190 staff and sells its products to more than 50 countries. ThromboView® is a registered trademark of AGEN Biomedical.

www.agenix.com

Contacts:

Nadine Padilla
VP, Corporate & Investor
Relations
Biosite Incorporated
(858) 455-4808 x3187
npadilla@biosite.com

February 16, 2005

**BIOSITE® INCORPORATED ANNOUNCES AVAILABILITY OF
TRIAGE® D-DIMER TEST IN THE UNITED STATES**

New Test Aids Emergency Physicians in Diagnosing Highly Lethal Conditions

SAN DIEGO – Biosite® Incorporated (Nasdaq: BSTE), a research-based provider of novel, rapid medical diagnostics, today announced the U.S. launch of its new, rapid, quantitative Triage® D-Dimer Test. The Triage D-Dimer Test aids in the assessment and evaluation of patients suspected of having thromboembolic events, including pulmonary embolism (PE) and deep vein thrombosis (DVT), which are common and potentially lethal conditions.

Portable and easy-to-use, this point-of-care diagnostic test provides D-dimer results in approximately 15 minutes and can be used in the emergency department or at a patient's bedside. The test uses highly sensitive immunoassay technology and the highly specific 3B6 D-dimer antibody.^{1,2,3} The Triage D-Dimer Test is run on the widely used Triage MeterPlus and correlates with other ELISA-based D-dimer tests.

"Pulmonary embolism is a time-critical and potentially life threatening condition. Because patients often present with vague symptoms, PE represents a clinical and diagnostic challenge," said Ken Buechler, Ph.D., Biosite's president and chief scientific officer. "We believe the Triage D-Dimer Test, used at the point-of-care, can help emergency department physicians rapidly evaluate patients suspected of having a thromboembolic event, which should result in better patient care."

In a recent single center study published in the *Annals of Emergency Medicine*, a point-of-care clinical protocol for the evaluation of PE using a commercially available rapid whole-blood immunochromatographic test for D-dimer doubled the number of patients evaluated for PE and

¹ Dempfle, C-E, Zips S, Ergul H, Heene D and the FACT Study Group, The Fibrin Assay Comparison Trial (FACT), *J Thromb Haemost* 2001; 85: 671-8.

² Stein and Hull et al, D-dimer for the Exclusion of Acute Venous Thrombosis and Pulmonary Embolism, *Ann Intern Med*. April 2004

³ Philip S. Wells, Evaluation of D-dimer in the Diagnosis of Suspected Deep-Vein Thrombosis, *NEJM*, 2003

decreased length of stay in the emergency department, without increasing the need for vascular imaging.⁴

Currently, more cases of PE are missed than are actually diagnosed because of vague and non-specific symptoms. PE is the third most common cause of death in the United States, with at least 650,000 cases occurring annually. It is the first or second most common cause of unexpected death in most age groups. The highest incidence of recognized PE occurs in hospitalized patients. Autopsy results show as many as 60 percent of patients dying in the hospital have had a PE, but the diagnosis has been missed in about 70 percent of the cases⁵.

In November 2003, Biosite signed an agreement with Brisbane-based biotechnology company Agenix Limited for a license to D-dimer technology and the commercial supply of the 3B6 D-dimer antibody.

About Biosite Incorporated

A leader in the drive to advance diagnosis, Biosite Incorporated is a research-based company dedicated to the discovery and development of novel protein-based diagnostics that improve a physician's ability to diagnose debilitating and life-threatening diseases. Through combined expertise in diagnostic discovery and commercialization, Biosite is able to access potential markers of disease, identify proteins with high diagnostic utility, develop and commercialize products and educate the medical community on new diagnostic approaches, thereby benefiting patients. Biosite's Triage[®] rapid diagnostics are used in approximately 50 percent of U.S. hospitals and in more than 50 international markets for toxicology screening and diagnosis of infectious and cardiovascular disease. Information on Biosite can be found at www.biosite.com.

Except for the historical information presented herein, matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including but not limited to statements that are preceded by, followed by, or that include the words "will"; "believes"; "should"; "intends"; "anticipates"; "plans"; "expects"; "estimates"; or similar statements are forward-looking statements. Forward looking statements include statements about the potential benefits of the Triage D-Dimer Test, and the commencement of marketing, education and sales of this new product. Risks and uncertainties include risks regarding the discovery and product development process generally, risks associated with the commencement of manufacturing the Triage D-Dimer Test on a commercial scale and risks related to the continued supply of AGEN's 3B6 antibody, specific for D-dimer. Other risks and uncertainties that may impact the Company's business generally include risks associated with the introduction of competitive products from companies with greater capital and resources, expansion or development of a direct sales effort in domestic and international markets, and risks and expenses associated with litigation, contract disputes, patent conflicts, product recalls, manufacturing constraints, backlog, delays or inefficiencies, shipment problems, seasonal customer demand, the timing of significant orders, changes in reimbursement policies, regulatory changes, competitive pressures on average selling prices, and the other risks including those detailed in the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other SEC filings. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Copies of the Company's public disclosure filings are available from the Investor Relations department.

###

*Biosite[®], Triage[®] and New Dimensions in Diagnosis[®] are registered trademarks of Biosite Incorporated. The Company's logo is a trademark of Biosite Incorporated.
3B6 D-dimer The Essential Element[™] is a trademark of AGEN[®] Biomedical LTD.*

⁴ J. Kline, et al. Ann Emerg Med. 2004; 44:490-502.

⁵ Feied CF: Pulmonary embolism. In: Rosen and Barken, eds, Emergency Medicine Principles and Practice, 4th ed. 1998; 3: Chapter 111.